Pipeline | MorphoSys AG

Phase 1
Phase 2
Phase 3
Market

15 Antibodies available:

Program

Partner

Indication

Phase

Tafasitamab-cxix (MOR208)

Partner

Incyte Corporation*

Indication

Phase

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)

Phase 1 Phase 2 Phase 3 Market (Current Phase)

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Diffuse large B-cell lymphoma (DLBCL) (frontMIND)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Diffuse large B-cell lymphoma (DLBCL) (firstMIND)

Phase 1 (Current Phase) Phase 2 Phase 3 Market

*Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

MOR208 (former XmAb®5574)
INN: tafasitamab
Target: CD19

More Information on Tafasitamab (MOR208)

Felzartamab (MOR202)

Partner

I-Mab Biopharma*

Indication

Phase

Multiple myeloma (MM) (combo with lenalidomide)*

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Multiple myeloma (MM)*

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Felzartamab (MOR202)

Partner

Indication

Phase

Anti-PLA2R-positive membranous nephropathy (New-PLACE)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Anti-PLA2R-positive membranous nephropathy (M-PLACE)

Phase 1 (Current Phase) Phase 2 Phase 3 Market

* Felzartamab (MOR202/TJ202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.

A fully human HuCAL antibody
Target: CD38

More Information on Felzartamab (MOR202)

Otilimab (MOR103/GSK3196165)

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid arthritis (contRAst 1-3)*

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Severe pulmonary COVID-19 related disease (OSCAR)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

*Fully outlicensed to GlaxoSmithKline.

A fully human HuCAL antibody
Target: GM-CSF

Gantenerumab

Partner

Roche

Indication

Phase

Early Alzheimer's disease (GRADUATE 1+2)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Mild Alzheimer's disease (Marguerite RoAD) (OLE)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Prodromal Alzheimer's disease (Scarlett RoAD) (OLE)

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Rollover study on long-term administration of gantenerumab

Phase 1 Phase 2 Phase 3 (Current Phase) Market

Alzheimer's disease (Brain Shuttle Gantenerumab, RG6102)

Phase 1 (Current Phase) Phase 2 Phase 3 Market

A fully human HuCAL antibody
Target: Amyloid-beta

Additional Information:

Study information on ClinicalTrials.gov

Ianalumab (VAY736)

Partner

Novartis

Indication

Phase

ADCC mediated B cell depletion & BAFF-R blockade (AMBER)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Idiopathic pulmonary fibrosis

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Systemic Lupus Erythematosus (SLE)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

A fully human HuCAL antibody
Target: BAFF-R

Additional information:

Study information on ClinicalTrials.gov

Abelacimab (MAA868)

Partner

Anthos Therapeutics

Indication

Phase

Atrial fibrillation

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Study information on ClinicalTrials.gov

NOV-8 (CMK389)

Partner

Novartis

Indication

Phase

Pulmonary Sarcoidosis

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Study information on ClinicalTrials.gov

NOV-9 (LKA651)

Partner

Novartis

Indication

Phase

Diabetic eye diseases

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Study information on ClinicalTrials.gov

Setrusumab (BPS804)

Partner

Novartis/Mereo/Ultragenyx

Indication

Phase

Brittle bone disease (Type I, III, IV) (ASTEROID)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

A fully human HuCAL antibody
Target: Sclerostin

Additional information:

Study information on ClinicalTrials.gov

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Solid tumors (combo with ISA101b vaccination)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Advanced Malignancies (combo with avelumab, PF-04518600 & CMP-001 (TLR9 agonist)) (JAVELIN Medley)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Advanced malignancies (combo with avelumab & PF-04518600)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Refractory large B cell lymphoma (combo with Axicabtagene ciloleucel) (ZUMA-11)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

A fully human HuCAL antibody
Target: 4-1BB (CD137)
Alias: PF-05082566

Additional Information:

Study information on ClinicalTrials.gov

Bimagrumab

Partner

Novartis

Indication

Phase

Type 2 diabetes

Phase 1 Phase 2 (Current Phase) Phase 3 Market

A fully human HuCAL antibody
Target: ActRIIB
Aliases: BYM338

Additional information:

Study information on ClinicalTrials.gov

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)

Phase 1 Phase 2 (Current Phase) Phase 3 Market

A fully human HuCAL antibody
Target: IGF-1

Additional Information:

Study information on ClinicalTrials.gov

NOV-14 (CSJ117)

Partner

Novartis

Indication

Phase

Asthma

Phase 1 Phase 2 (Current Phase) Phase 3 Market

Target: TSLP

Additional Information:

Study information on ClinicalTrials.gov

MOR210

Partner

I-Mab Biopharma*

Indication

Phase

Relapsed or refractory advanced solid tumors

Phase 1 (Current Phase) Phase 2 Phase 3 Market

* I-Mab receives exclusive rights in China, Hong Kong, Macao, Taiwan and South Korea, while MorphoSys retains rights in other parts of the world.